{
    "nctId": "NCT03355469",
    "officialTitle": "Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome",
    "inclusionCriteria": "* Male or female \\>40 and \\<70 years old.\n* Has a body mass index \\>27 and \\<47 kg/m2.\n* Not diagnosed with Type 2 diabetes.\n* Not currently engaged in \\> 60 min/wk of exercise\n* Meet at least 3 of 5 National Cholesterol Education Adult Treatment Panel III\n\nMetabolic Syndrome criteria:\n\n* Increased waist circumference (\u2265102 cm in men; \u226588 cm in women)\n* Elevated triglycerides (\u2265150 mg/dl), or on medication for treating the condition\n* Reduced HDL-cholesterol (\\<40mg/dl in men, \\<50 mg/dl in women), or on medication for treating the condition\n* High blood pressure (\u2265130 mmHg systolic or \u226585mmHg diastolic), or on medication for treating the condition\n* Elevated fasting glucose (\u2265100 mg/dl), or on medication for treating the condition\n* Must have minimum age of 40 Years\n* Must have maximum age of 70 Years",
    "exclusionCriteria": "* Morbidly obese patients (BMI \\>47 kg/m2) and overweight/lean patients (BMI \\<27 kg/m2)\n* Evidence of type 1 diabetes and diabetics requiring insulin therapy.\n* Subjects who have not been weight stable (\\>2 kg weight change in past 3 months)\n* Subjects who have been recently active (\\>30 min of moderate/high intensity exercise, 2 times/week).\n* Subjects who are smokers or who have quit smoking \\<5 years ago\n* Subjects prescribed metformin or have taken metformin within 1 year.\n* Subjects with abnormal estimated glomerular filtration rate (eGFR).\n* Hypertriglyceridemic (\\>400 mg/dl) and hypercholesterolemic (\\>260 mg/dl) subjects\n* Hypertensive (\\>160/100 mmHg)\n* Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).\n* Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures, or impact subject safety.\n* Pregnant (as evidenced by positive pregnancy test) or nursing women\n* Subjects with contraindications to participation in an exercise training program\n* Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzephetamine, diethylpropion, phendimetrazine)\n* Known hypersensitivity to perflutren (contained in Definity)"
}